CRUK launches RadNet network to lead next generation of radiotherapy research
Date published: Nov 04 2019
The National Cancer Research Institute (NCRI) welcomes today’s announcement that £56 million will be invested in a new radiotherapy research network in the UK pioneering the use of the latest techniques such as artificial intelligence, proton beam therapy, FLASH radiotherapy and developing novel drug-radiotherapy combinations.
Cancer Research UK’s executive director of research and innovation, Dr Iain Foulkes, is announcing the radiotherapy network at 11am today (Monday) at the National Cancer Research Institute (NCRI) conference in Glasgow, during the session Celebrating collaborative radiotherapy research in the UK – CTRad 10 years on.
The RadNet network, funded by Cancer Research UK (CRUK), aims to improve cancer survival by optimising and personalising radiotherapy. NCRI’s Clinical and Translational Radiotherapy Research Working Group (CTRad) was set up in 2009 and is the NCRI’s flagship initiative. It was established by NCRI to support the complex and challenging area of radiotherapy research in the UK and played a pivotal role in the establishment of this network.
In 2016 CTRad completed a pioneering benchmarking exercise to define internationally relevant criteria for measuring the quality of multidisciplinary radiotherapy research, identifying centres as either ‘Centres of Excellence’ or ‘Emerging Centres of Excellence’. This work informed CRUK’s independent review of radiation research that resulted in the launch of the CRUK RadNet initiative.
CTRad will engage with the seven centres of excellence that will make up the RadNet network, and the UK radiotherapy research community, to accelerate the development of advanced radiotherapy techniques with the integration of biology, to make radiotherapy more effective.
Dr Iain Frame, CEO, NCRI, said, “On behalf of our patients and researchers, the NCRI welcomes this network-wide investment in radiotherapy research, a key milestone in our commitment to accelerating progress in cancer-related research. Through our flagship initiative, CTRad, we will continue to drive collaborative working and will work with our partners to secure further opportunities at a national scale for the benefit of patients.”